Status: Recruiting
A Phase 1 Study of ATORM-C in Patients With Crohn's Disease
This Phase 1 study evaluates the safety and tolerability of ATORM-C in patients with Crohn's disease. ATORM-C is an investigational product consisting of autologous adult stem cell-derived intestinal organoids. Participants will receive a single dose of ATORM-C applied directly to a target intestinal ulcer during colonoscopy. The study will also explore the effect of ATORM-C on intestinal ulcer healing.
Participants needed: 18
Trial details
Phase: Phase 1Age: 19-80Biological sex: AllType: InterventionalSponsor: ORGANOIDSCIENCES LTD.Updated: Sep 16, 2026Locations: 1
Eligibility criteria
Aged 19 years or older and younger than 80 years at the time of screening (male... [+8]
Other Inflammatory Bowel Conditions: Diagnosed with ulcerative colitis or unclas... [+13]